Timothy Rolph, DPhil
2021
In 2021, Timothy Rolph, DPhil earned a total compensation of $1.8M as Chief Scientific Officer at Akero Therapeutics, a 11% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $171,396 |
|---|---|
| Option Awards | $1,190,645 |
| Salary | $428,490 |
| Total | $1,790,531 |
DPhil received $1.2M in option awards, accounting for 66% of the total pay in 2021.
DPhil also received $171.4K in non-equity incentive plan and $428.5K in salary.
Rankings
In 2021, Timothy Rolph, DPhil's compensation ranked 6,477th out of 12,415 executives tracked by ExecPay. In other words, DPhil earned more than 47.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,477 out of 12,415 | 48th |
Division Manufacturing | 2,776 out of 5,508 | 50th |
Major group Chemicals And Allied Products | 1,225 out of 2,378 | 49th |
Industry group Drugs | 1,092 out of 2,099 | 48th |
Industry Pharmaceutical Preparations | 792 out of 1,549 | 49th |
Source: SEC filing on April 28, 2023.
DPhil's colleagues
We found four more compensation records of executives who worked with Timothy Rolph, DPhil at Akero Therapeutics in 2021.